HNWAG
JAZZ icon

High Net Worth Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

High Net Worth Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed -$1K – 698
2022
Q1 		$1K Hold
4
– – ﹤0.01% 664
2021
Q4 		$1K Buy
+4
New +$526 ﹤0.01% 672

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

High Net Worth Advisory Group's JAZZ Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 4 shares — an estimated $1K sold.

High Net Worth Advisory Group first reported a position in JAZZ in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 4 Jazz Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • High Net Worth Advisory Group first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • High Net Worth Advisory Group's Jazz Pharmaceuticals position peaked at $1K in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.